Innovative Therapies in Systemic Lupus Erythematosus

Roberta Fenoglio, Fernando Fervenza, Dario Roccatello

Research output: Chapter in Book/Report/Conference proceedingChapter


Systemic lupus erythematosus (SLE) is a chronic autoimmune condition with unpredictable course, with periods of flares and remission. SLE is characterized by a broad spectrum of clinical manifestations and varying patterns of disease activity. The efficacy of current SLE medication has been questioned by treatment-related adverse side effects secondary to corticosteroid use and untargeted immunosuppression and by the increasing number of patients with refractory disease. Over the last decades, there has been major progress in the understanding of the immunopathology of SLE, paving the way for the development of new biological agents, potentially revolutionizing the treatment of SLE. A variety of novel therapeutic targets have been identified and there have been many studies in patients with SLE in an attempt to translate these new treatments into clinical practice.

Original languageEnglish (US)
Title of host publicationRare Diseases of the Immune System
PublisherSpringer Nature
Number of pages23
StatePublished - 2016

Publication series

NameRare Diseases of the Immune System
ISSN (Print)2282-6505
ISSN (Electronic)2283-6403


  • Belimumab
  • Immunosuppression
  • Rituximab
  • Systemic lupus erythematosus
  • Target therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Genetics(clinical)


Dive into the research topics of 'Innovative Therapies in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this